Novartis Cancer Drug Suits Too Few To Centralize, JPML Told
Novartis Pharmaceuticals Inc. told the Judicial Panel on Multidistrict Litigation on Thursday that suits alleging its blood cancer drug Tasigna causes cardiovascular disease should not be consolidated, since the company believes it...To view the full article, register now.
Already a subscriber? Click here to view full article